TY - JOUR
T1 - THIP treatment of huntington’s disease
AU - Foster, N. L.
AU - Chase, T. N.
AU - Denaro, A.
AU - Hare, T. A.
AU - Tamminga, C. A.
PY - 1983/5
Y1 - 1983/5
N2 - We evaluated the therapeutic efficacy of gamma aminobutyric acid (GABA) system stimulation in four patients with classical Huntington’s disease and one with the hypokinetic-rigid form. Orally administered THIP (4,5,6,7-tetrahydroisoxazolo-[5,4,-c] pyridin-3-ol), a novel GABA receptor agonist, failed to improve motor or cognitive function during a 2-week trial. At maximum levels, THIP mimicked another putative GABA agonist, muscimol, in causing unsteadiness of gait, diminished attention to sensory stimuli, and somnolence. These effects suggest that central GABA systems participate in the regulation of some human and behavioral functions. CSF content of homovanillic acid, a major metabolite of dopamine, increased during high-dose THIP therapy, suggesting that augmentation of dopaminergic function may have contributed to the drug’s lack of efficacy.
AB - We evaluated the therapeutic efficacy of gamma aminobutyric acid (GABA) system stimulation in four patients with classical Huntington’s disease and one with the hypokinetic-rigid form. Orally administered THIP (4,5,6,7-tetrahydroisoxazolo-[5,4,-c] pyridin-3-ol), a novel GABA receptor agonist, failed to improve motor or cognitive function during a 2-week trial. At maximum levels, THIP mimicked another putative GABA agonist, muscimol, in causing unsteadiness of gait, diminished attention to sensory stimuli, and somnolence. These effects suggest that central GABA systems participate in the regulation of some human and behavioral functions. CSF content of homovanillic acid, a major metabolite of dopamine, increased during high-dose THIP therapy, suggesting that augmentation of dopaminergic function may have contributed to the drug’s lack of efficacy.
UR - http://www.scopus.com/inward/record.url?scp=0020597536&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020597536&partnerID=8YFLogxK
U2 - 10.1212/wnl.33.5.637
DO - 10.1212/wnl.33.5.637
M3 - Article
C2 - 6221200
AN - SCOPUS:0020597536
SN - 0028-3878
VL - 33
SP - 637
EP - 639
JO - Neurology
JF - Neurology
IS - 5
ER -